These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 26212480)

  • 1. Reply: Re: Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson's Disease in the UK and Germany.
    Walter E; Odin P
    J Med Econ; 2015 Nov; 18(11):860-2. PubMed ID: 26212480
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson's Disease in the UK and Germany.
    Barnett G; Williams AC
    J Med Econ; 2015 Nov; 18(11):858-9. PubMed ID: 26121159
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson's disease in the UK and Germany.
    Walter E; Odin P
    J Med Econ; 2015 Feb; 18(2):155-65. PubMed ID: 25348011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Continuous subcutaneous infusion of apomorphine for the treatment of Parkinson's disease].
    Drapier S; Vérin M
    Rev Neurol (Paris); 2006 Oct; 162(10):1019-23. PubMed ID: 17028572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apomorphine-subcutaneous--Bertek/Britannia.
    Drugs R D; 2004; 5(4):211-2. PubMed ID: 15230626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D; Hanssens Y; Northway MG
    Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prevalence and main methods of treatment of advanced stages of Parkinson's disease].
    Seliverstov IuA; Illarioshkin SN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(11):100-6. PubMed ID: 24479164
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost-Effectiveness of Device-Aided Therapies in Parkinson's Disease: A Structured Review.
    Smilowska K; van Wamelen DJ; Pietrzykowski T; Calvano A; Rodriguez-Blazquez C; Martinez-Martin P; Odin P; Chaudhuri KR
    J Parkinsons Dis; 2021; 11(2):475-489. PubMed ID: 33386813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous subcutaneous infusion of apomorphine can be used safely in patients with Parkinson's disease and pre-existing visual hallucinations.
    van Laar T; Postma AG; Drent M
    Parkinsonism Relat Disord; 2010 Jan; 16(1):71-2. PubMed ID: 19524477
    [No Abstract]   [Full Text] [Related]  

  • 10. [The concept of continuous dopaminergic stimulation in the treatment of late stages of Parkinson's disease].
    Titova NV; Katunina EA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(12):105-12. PubMed ID: 24596973
    [No Abstract]   [Full Text] [Related]  

  • 11. Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications.
    Colosimo C; Merello M; Hughes AJ; Sieradzan K; Lees AJ
    Neurology; 1998 Feb; 50(2):573-4. PubMed ID: 9484410
    [No Abstract]   [Full Text] [Related]  

  • 12. Extra cost of subcutaneous apomorphine would pay for personal nurses.
    Hill-Smith I
    BMJ; 1998 Aug; 317(7158):602. PubMed ID: 9721130
    [No Abstract]   [Full Text] [Related]  

  • 13. [Cost analysis in Italy of various strategies for the treatment of Parkinson disease in the advanced phase].
    D'Ausilio A; Marconi S; Antonini A; Tamma F; Valzania F; Berto P
    Recenti Prog Med; 2003 Nov; 94(11):484-93. PubMed ID: 14679916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New treatment for people with Parkinson's.
    FDA Consum; 2004; 38(4):5. PubMed ID: 15346564
    [No Abstract]   [Full Text] [Related]  

  • 15. Drug for "off" episodes of Parkinson's--effective but limited.
    Mayo Clin Health Lett; 2005 Jul; 23(7):4. PubMed ID: 16189845
    [No Abstract]   [Full Text] [Related]  

  • 16. New drug helps Parkinson's "off" periods.
    Health News; 2004 Jul; 10(7):2. PubMed ID: 15239150
    [No Abstract]   [Full Text] [Related]  

  • 17. [Subcutaneous continuous apomorphine infusion: treatment initiation and follow up].
    Grandas FJ; Sesar-Ignacio Á
    Rev Neurol; 2012; 55 Suppl 1():S21-4. PubMed ID: 23169229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apomorphine for the acute treatment of "off" episodes in Parkinson's disease.
    Stacy M; Silver D
    Parkinsonism Relat Disord; 2008; 14(2):85-92. PubMed ID: 18083605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Practical use of continuous apomorphine infusion via pump].
    Tönges L; Ceballos-Baumann A; Honig H; Storch A; Jost WH
    Fortschr Neurol Psychiatr; 2017 Sep; 85(9):516-535. PubMed ID: 28817841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apomorphine hydrochloride for the treatment of Parkinson's disease.
    Unti E; Ceravolo R; Bonuccelli U
    Expert Rev Neurother; 2015; 15(7):723-32. PubMed ID: 26037961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.